Ichthyosis: Clinical manifestations and practical treatment options

American Journal of Clinical Dermatology

Volumn 10, Issue 6, 2009, Pages 351-364

  Oji, Vinzenz ^a   Traupe, Heiko ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIINFECTIVE AGENT; DEXPANTHENOL; ETRETIN; GLYCEROL; HUMECTANT; KERATOLYTIC AGENT; LACTIC ACID; LIAROZOLE; PROPYLENE GLYCOL; RETINOIC ACID; RETINOID; SALICYLIC ACID; SODIUM CHLORIDE; TAZAROTENE; UREA; XIPAMIDE;

BATH; BULLOUS DERMATITIS; CONGENITAL ICHTHYOSIFORM ERYTHRODERMA; CREAM; FAMILY HISTORY; GENETIC COUNSELING; HUMAN; ICHTHYOSIS; ICHTHYOSIS VULGARIS; INFLAMMATION; INTEGUMENT; LABORATORY DIAGNOSIS; LAMELLAR ICHTHYOSIS; NETHERTON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; REVIEW; SKIN BIOPSY; SKIN BURNING SENSATION; SKIN IRRITATION; SYMPTOMATOLOGY; TERATOGENICITY; X LINKED ICHTHYOSIS;

HUMANS; ICHTHYOSIS;

EID: 70350340708     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11311070-000000000-00000     Document Type: Review

References (79)

1. Traupe H. The ichthyosis: a guide to clinical diagnosis, genetic counseling, and therapy. Berlin: Springer Verlag, 1989: 111-134
2. Oji V, Traupe H. Ichthyoses: differential diagnosis and molecular genetics. Eur J Dermatol 2006; 16: 349-359
3. Oji, V, Tadini, G, Akiyama, M, et al. Revised nomenclature and classification of inherited ichthyoses. Ichthyosis Consensus Conference; 2009 Jan 23-24; Sorè ze [online]. Available from URL: http://www.netzwerk- ichthyose.de/ index.php?id=28&L=1 [Accessed 2009 Sep 21]
4. OjiV.Update of themoderation process of the ichthyosis classification. Ichthyosis Consensus Conference; 2009 Jan 23-24; Sorè ze [online]. Available from URL: http://www.netzwerk-ichthyose.de/index.php?id=28&L=1 [Accessed 2009 Sep 21].
5. Classification of congenital ichthyosis. First World Conference on Ichthyosis; 2007 Aug 31-Sep 2; Münster
6. Elias PM, Williams ML, Holleran WM, et al. Thematic review series: skin lipids. Pathogenesis of permeability barrier abnormalities in the ichthyoses: inherited disorders of lipid metabolism. J Lipid Res 2008; 49: 697-714
7. SchmuthM, Gruber R, Elias PM, et al. Ichthyosis update: towards a functiondriven model of pathogenesis of the disorders of cornification and the role of corneocyte proteins in these disorders. Adv Dermatol 2007; 23: 231-256
8. DiGiovanna JJ. Ichthyosiform dermatoses: so many discoveries, so little progress. J Am Acad Dermatol 2004; 51: S31-4
9. Wells RS, Kerr CB. Genetic classification of ichthyosis. Arch Dermatol 1965; 92: 1-6
10. Wells RS, Jennings MC. X-linked ichthyosis and ichthyosis vulgaris: clinical and genetic distinctions in a second series of families. JAMA 1967; 202: 485-488
11. Smith FJ, Irvine AD, Terron-Kwiatkowski A, et al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. NatGenet 2006; 38: 337-342
12. Liao H, Waters AJ, Goudie DR, et al. Filaggrin mutations are genetic modifying factors exacerbating X-linked ichthyosis. J Invest Dermatol 2007; 127: 2795-2798
13. Webster D, France JT, Shapiro LJ, et al. X-linked ichthyosis due to steroidsulphatase deficiency. Lancet 1978; I: 70-72
14. Ballabio A, Parenti G, Carrozzo R, et al. Isolation and characterization of a steroid sulfatase cDNA clone: genomic deletions in patients with X-chromosome-linked ichthyosis. Proc Natl Acad SciUSA1987; 84: 4519-4523
15. Hernandez-Martin A, Gonzalez-Sarmiento R, De Unamuno P. X-linked ichthyosis: an update. Br J Dermatol 1999; 141: 617-627
16. Akiyama M, Sakai K, Sato T, et al. Compound heterozygous ABCA12 mutations including a novel nonsense mutation underlie harlequin ichthyosis. Dermatology 2007; 215: 155-159
17. Kelsell DP, Norgett EE, Unsworth H, et al. Mutations in ABCA12 underlie the severe congenital skin disease harlequin ichthyosis. Am J Hum Genet 2005; 76: 794-803
18. Lefevre C, Audebert S, Jobard F, et al.Mutations in the transporter ABCA12 are associated with lamellar ichthyosis type 2. Hum Mol Genet 2003; 12: 2369-2378
19. Akiyama M, Sawamura D, Shimizu H. The clinical spectrum of nonbullous congenital ichthyosiform erythroderma and lamellar ichthyosis. Clin Exp Dermatol 2003; 28: 235-240
20. Oji V, Hautier JM, Ahvazi B, et al. Bathing suit ichthyosis is caused by transglutaminase-1 deficiency: evidence for a temperature-sensitive phenotype. Hum Mol Genet 2006; 15: 3083-3097
21. Raghunath M, Hennies HC, Ahvazi B, et al. Self-healing collodion baby: a dynamic phenotype explained by a particular transglutaminase-1 mutation. J Invest Dermatol 2003; 120: 224-228
22. HartingM, Brunetti-PierriN, Chan CS, et al. Self-healing collodionmembrane and mild nonbullous congenital ichthyosiform erythroderma due to 2 novel mutations in the ALOX12B gene. Arch Dermatol 2008; 144: 351-356
23. Lefevre C, Bouadjar B, Ferrand V, et al. Mutations in a new cytochrome P450 gene in lamellar ichthyosis type 3. Hum Mol Genet 2006; 15: 767-776
24. Jobard F, Lefevre C, Karaduman A, et al. Lipoxygenase-3 (ALOXE3) and 12(R)-lipoxygenase (ALOX12B) are mutated in non-bullous congenital ichthyosiform ichthyosiform erythroderma (NCIE) linked to chromosome 17p13.1. Hum Mol Genet 2002; 11: 107-113
25. Lefevre C, Bouadjar B, Karaduman A, et al. Mutations in ichthyin a new gene on chromosome 5q33 in a new form of autosomal recessive congenital ichthyosis. Hum Mol Genet 2004; 13: 2473-2482
26. Compton JG, DiGiovanna JJ, Santucci SK, et al. Linkage of epidermolytic hyperkeratosis to the type II keratin gene cluster on chromosome 12q. Nat Genet 1992; 1: 301-305
27. Rothnagel JA, Dominey AM, Dempsey LD, et al. Mutations in the rod domains of keratins 1 and 10 in epidermolytic hyperkeratosis. Science 1992; 257: 1128-1130
28. Steijlen PM, Perret CM, Schuurmans Stekhoven JH, et al. Ichthyosis bullosa of Siemens: further delineation of the phenotype. Arch Dermatol Res 1990; 282: 1-5
29. Jansen GA, Ofman R, Ferdinandusse S, et al. Refsum disease is caused by mutations in the phytanoyl-CoAhydroxylase gene. NatGenet 1997; 17: 190-193
30. Jansen GA, Waterham HR, Wanders RJ. Molecular basis of Refsum disease: sequence variations in phytanoyl-CoA hydroxylase (PHYH) and the PTS2 receptor (PEX7). Hum Mutat 2004; 23: 209-218
31. Eldjarn L, TryK, Stokke O, et al. Dietary effects on serum-phytanic-acid levels and on clinical manifestations in heredopathia atactica polyneuritiformis. Lancet 1966; I: 691-693
32. Sprecher E, Chavanas S, DiGiovanna JJ, et al. The spectrum of pathogenic mutations in SPINK5 in 19 families with Netherton syndrome: implications for mutation detection and first case of prenatal diagnosis. J Invest Dermatol 2001; 117: 179-187
33. Chavanas S, Bodemer C, Rochat A, et al. Mutations in SPINK5, encoding a serine protease inhibitor, causeNetherton syndrome.Nat Genet 2000; 25: 141-142
34. Komatsu N, Takata M, Otsuki N, et al. Elevated stratum corneum hydrolytic activity in Netherton syndrome suggests an inhibitory regulation of desquamation by SPINK5-derived peptides. J Invest Dermatol 2002; 118: 436-443
35. De Laurenzi V, Rogers GR, Hamrock DJ, et al. Sjogren-Larsson syndrome is caused by mutations in the fatty aldehyde dehydrogenase gene. Nat Genet 1996; 12: 52-57
36. GordonN. Sjogren-Larsson syndrome. DevMed Child Neurol 2007; 49: 152-154
37. Lefevre C, Jobard F, Caux F, et al. Mutations in CGI-58, the gene encoding a new protein of the esterase/lipase/thioesterase subfamily, in Chanarin- Dorfman syndrome. Am J Hum Genet 2001; 69: 1002-1012
38. Angelini C, Philippart M, Borrone C, et al. Multisystem triglyceride storage disorder with impaired long-chain fatty acid oxidation. Ann Neurol 1980; 7: 5-10
39. Faghri S, Tamura D, Kraemer KH, et al. Trichothiodystrophy: a systematic review of 112 published cases characterises a wide spectrum of clinical manifestations. J Med Genet 2008; 45: 609-621
40. Patel N, Spencer LA, English III JC, et al. Acquired ichthyosis. J Am Acad Dermatol 2006; 55: 647-656
41. Dale BA, Holbrook KA, Fleckman P, et al. Heterogeneity in harlequin ichthyosis, an inborn error of epidermal keratinization: variable morphology and structural protein expression and a defect in lamellar granules. J Invest Dermatol 1990; 94: 6-18
42. Elias PM, Williams ML. Neutral lipid storage disease with ichthyosis: defective lamellar body contents and intracellular dispersion. Arch Dermatol 1985; 121: 1000-1008
43. Dahlqvist J, Klar J, Hausser I, et al. Congenital ichthyosis: mutations in ichthyin are associated with specific structural abnormalities in the granular layer of epidermis. J Med Genet 2007; 44: 615-620
44. Ishida-Yamamoto A, Richard G, Takahashi H, et al. In vivo studies of mutant keratin 1 in ichthyosis hystrix Curth-Macklin. J Invest Dermatol 2003; 120: 498-500
45. Ong C, O'Toole EA, Ghali L, et al. LEKTI demonstrable by immunohistochemistry of the skin: a potential diagnostic skin test for Netherton syndrome. Br J Dermatol 2004; 151: 1253-1257
46. Raghunath M, Tontsidou L, Oji V, et al. SPINK5 and Netherton syndrome: novel mutations, demonstration of missing LEKTI, and differential expression of transglutaminases. J Invest Dermatol 2004; 123: 474-483
47. Raghunath M, Hennies HC, Velten F, et al. A novel in situ method for the detection of deficient transglutaminase activity in the skin. Arch Dermatol Res 1998; 290: 621-627
48. Verfaille CJ, Vanhoutte FP, Blanchet-Bardon C, et al. Oral liarozole versus acitretin in the treatment of ichthyosis: a phase II/III multicentre, doubleblind, randomized, active-controlled study. Br J Dermatol 2007; 156: 965-973
49. Okano M. Assessment of the clinical effect of topical tacalcitol on ichthyoses with retentive hyperkeratosis. Dermatology 2001; 202: 116-118
50. Lucker GP, Heremans AM, Boegheim PJ, et al. Oral treatment of ichthyosis by the cytochrome P-450 inhibitor liarozole. Br J Dermatol 1997; 136: 71-75
51. Lucker GP, Verfaille CJ, Heremans AM, et al. Topical liarozole in ichthyosis: a double-blind, left-right comparative study followed by a long-term open maintenance study. Br J Dermatol 2005; 152: 566-569
52. Kuster W, Bohnsack K, Rippke F, et al. Efficacy of urea therapy in children with ichthyosis: a multicenter randomized, placebo-controlled, double-blind, semilateral study. Dermatology 1998; 196: 217-222
53. Kragballe K, Steijlen PM, Ibsen HH, et al. Efficacy, tolerability, and safety of calcipotriol ointment in disorders of keratinization: results of a randomized, double-blind, vehicle-controlled, right/left comparative study. Arch Dermatol 1995; 131: 556-560
54. Kempers S, Katz HI,Wildnauer R, et al. An evaluation of the effect of an alpha hydroxy acid-blend skin cream in the cosmetic improvement of symptoms of moderate to severe xerosis, epidermolytic hyperkeratosis, and ichthyosis. Cutis 1998; 61: 347-350
55. Ganemo A, Virtanen M, Vahlquist A. Improved topical treatment of lamellar ichthyosis: a double-blind study of four different cream formulations. Br J Dermatol 1999; 141: 1027-1032
56. DiGiovanna JJ, Robinson-Bostom L. Ichthyosis: etiology, diagnosis, and management. Am J Clin Dermatol 2003; 4: 81-95
57. Kuster W. Ichthyoses: suggestions for an improved therapy. Deutsches Arzteblatt 2006; 103: 1484-1489
58. Shwayder T. Disorders of keratinization: diagnosis and management. Am J Clin Dermatol 2004; 5: 17-29
59. Traupe H, Burgdorf WHC. Treatment of ichthyosis: there is always something you can do! In memoriam: Wolfgang Küster. Am Acad Dermatol 2007; 57: 542-547
60. Vahlquist A, Ganemo A, Virtanen M. Congenital ichthyosis: an overview of current and emerging therapies. Acta Derm Venereol 2008; 88: 4-14
61. Elias PM, Williams ML, Holleran WM, et al. Thematic review series: skin lipids. Pathogenesis of permeability barrier abnormalities in the ichthyoses: inherited disorders of lipid metabolism. J Lipid Res 2008; 49: 697-714
62. Hofmann B, Stege H, Ruzicka T, et al. Effect of topical tazarotene in the treatment of congenital ichthyoses. Br J Dermatol 1999; 141: 642-646
63. Nguyen V, Cunningham BB, Eichenfield LF, et al. Treatment of ichthyosiform diseases with topically applied tazarotene: risk of systemic absorption. J Am Acad Dermatol 2007; 57 (5 Suppl.): S123-5
64. Cotellessa C, Cuevas-Covarrubias SA, Valeri P, et al. Topical tazarotene 0.05% versus glycolic acid 70% treatment in X-linked ichthyosis due to extensive deletion of the STS gene. Acta Derm Venereol 2005; 85: 346-348
65. Yamamura S, Kinoshita Y, Kitamura N, et al. Neonatal salicylate poisoning during the treatment of a collodion baby. Clin Pediatr (Phila) 2002; 41: 451-452
66. Singh S, Bhura M, Maheshwari A, et al. Successful treatment of harlequin ichthyosis with acitretin. Int J Dermatol 2001; 40: 472-473
67. Lawlor F, Peiris S. Harlequin fetus successfully treated with etretinate. Br J Dermatol 1985; 112: 585-590 (Pubitemid 15060999)
68. Ozturk A, Caksen H, Cetin N, et al. A retrospective study on 16 collodion babies. Turk J Pediatr 1997; 39: 55-59
69. Hachem JP, Houben E, Crumrine D, et al. Serine protease signaling of epidermal permeability barrier homeostasis. J Invest Dermatol 2006; 126: 2074-2086
70. Haenssle HA, Finkenrath A, Hausser I, et al. Effective treatment of severe thermodysregulation by oral retinoids in a patient with recessive congenital lamellar ichthyosis. Clin Exp Dermatol 2008; 33 (5): 578-581
71. Oji V, Beljan G, Beier K, et al. Topical pimecrolimus: a novel therapeutic option for Netherton syndrome. Br J Dermatol 2005; 153: 1067-1068
72. Allen A, Siegfried E, Silverman R, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 2001; 137: 747-750
73. Lacour M, Mehta-Nikhar B, Atherton DJ, et al. An appraisal of acitretin therapy in children with inherited disorders of keratinization. Br J Dermatol 1996; 134: 1023-1029
74. Steijlen PM, Van Dooren-Greebe RJ, Happle R, et al. Ichthyosis bullosa of Siemens responds well to low-dosage oral retinoids. Br J Dermatol 1991; 125: 469-471
75. Berth-Jones J, Todd G, Hutchinson PE, et al. Treatment of psoriasis with oral liarozole: a dose-ranging study. Br J Dermatol 2000; 143: 1170-1176
76. Akiyama M, Titeux M, Sakai K, et al. DNA-based prenatal diagnosis of harlequin ichthyosis and characterization of ABCA12 mutation consequences. J Invest Dermatol 2007; 127: 568-573
77. Bitoun E, Bodemer C, Amiel J, et al. Prenatal diagnosis of a lethal form of Netherton syndrome by SPINK5 mutation analysis. Prenat Diagn 2002; 22: 121-126
78. Rothnagel JA, Lin MT, Longley MA, et al. Prenatal diagnosis for keratin mutations to exclude transmission of epidermolytic hyperkeratosis. Prenat Diagn 1998; 18: 826-830
79. Fassihi H, Eady RA, Mellerio JE, et al. Prenatal diagnosis for severe inherited skin disorders: 25 years' experience. Br J Dermatol 2006; 154: 106-113